VF
BDRX

Virtu Financial’s Biodexa Pharmaceuticals BDRX Stock Holding History

Virtu Financial’s Portfolio BDRX Stock Details BDRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-29
Closed -$32K – 1374
2024
Q2 		$32K Buy
+29
New +$38K ﹤0.01% 967
2023
Q2 		– Hold
0
– -$18K – 1517
2023
Q1 		– Hold
0
– – – 1259
2021
Q3 		– Hold
0
– -$35K – 1511
2021
Q2 		– Hold
0
– – – 1377
2021
Q1 		– Hold
0
– – – 1309
2020
Q4 		– Hold
0
– – – 1061
2019
Q4 		– Hold
0
– – – 1227
2019
Q1 		– Hold
0
– -$3K – 1411
2018
Q4 		– Hold
0
– – – 1494
2018
Q3 		– Hold
0
– -$7K – 1547
2018
Q2 		– Hold
0
– – – 1913

Other funds holding BDRX

UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
TSS
Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
RhumbLine Advisers
RhumbLine Advisers Boston, Massachusetts $133B AUM 43.5% 1-Year Est. Return
CIM
Contravisory Investment Management Norwell, Massachusetts $566M AUM 42.93% 1-Year Est. Return
GI
GAMMA Investing Foster City, California $2.69B AUM 42.78% 1-Year Est. Return

Virtu Financial's BDRX Position: Q3 2024 in Review

Virtu Financial sold out of Biodexa Pharmaceuticals (BDRX) in Q3 2024, closing a stake of 29 shares — an estimated $32K sold.

Virtu Financial first reported a position in BDRX in Q2 2024 and held it in 1 quarter. The position peaked at $32K in Q2 2024. 5 funds tracked by Wall St. Rank hold BDRX as of Q3 2024.

  • Virtu Financial reported no remaining Biodexa Pharmaceuticals position as of Q3 2024 after selling out during the quarter.
  • Virtu Financial sold 29 Biodexa Pharmaceuticals shares in Q3 2024, an estimated $32K.
  • Virtu Financial first reported a position in Biodexa Pharmaceuticals in Q2 2024 and held it in 1 quarter.
  • Virtu Financial's Biodexa Pharmaceuticals position peaked at $32K in Q2 2024.
  • 5 funds tracked by Wall St. Rank held Biodexa Pharmaceuticals as of Q3 2024.

Based on Virtu Financial's 13F filing for Q3 2024, filed 20 Nov 2024.